Suppr超能文献

用于心血管疾病预防的新疗法。

Novel treatments for cardiovascular disease prevention.

机构信息

Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

出版信息

Cardiovasc Ther. 2012 Oct;30(5):257-63. doi: 10.1111/j.1755-5922.2011.00280.x. Epub 2011 May 31.

Abstract

The purpose of this review is to describe novel pharmacologic and nonpharmacologic preventive therapies, as well as new strategies to improve delivery of available therapies. Cardiovascular disease (CVD) is the leading cause of death worldwide, and prevention plays a critical role in curbing the global epidemic. Despite available treatment for tobacco addiction, platelet inhibition, blood pressure, and lipid lowering for reduction of atherosclerotic disease, significant gaps in treatment of total CVD remain. We review a range of new preventive treatment options, including drugs for tobacco cessation, platelet/thrombotic inhibition, lipid- and blood pressure-lowering; nonpharmacologic options such as left atrial appendage closure devices and caloric restriction; and strategies such as fixed-dose combination drugs, laboratory screening for drug tailoring, and community-based prevention programs. CVD preventive research continues to evolve and provide clinicians and patients with novel pharmacologic and nonpharmacologic therapies, including new preventive strategies.

摘要

本综述旨在描述新型的药物和非药物预防疗法,以及改善现有治疗方法应用的新策略。心血管疾病 (CVD) 是全球范围内的主要致死原因,预防对于遏制这一全球流行疾病至关重要。尽管有针对烟草成瘾、血小板抑制、血压和血脂降低以减少动脉粥样硬化疾病的治疗方法,但在 CVD 的整体治疗方面仍存在显著差距。我们回顾了一系列新的预防治疗选择,包括用于戒烟、血小板/血栓抑制、降脂和降压的药物;非药物选择,如左心耳封堵装置和热量限制;以及固定剂量联合药物、药物定制的实验室筛查和基于社区的预防计划等策略。CVD 预防研究不断发展,为临床医生和患者提供新型的药物和非药物治疗方法,包括新的预防策略。

相似文献

1
Novel treatments for cardiovascular disease prevention.
Cardiovasc Ther. 2012 Oct;30(5):257-63. doi: 10.1111/j.1755-5922.2011.00280.x. Epub 2011 May 31.
2
Comprehensive medical management of peripheral arterial disease.
Prog Cardiovasc Dis. 2011 Jul-Aug;54(1):2-13. doi: 10.1016/j.pcad.2011.02.004.
3
Prevention of cardiovascular events in elderly people.
Drugs Aging. 2005;22(10):859-76. doi: 10.2165/00002512-200522100-00005.
4
Reducing the cardiovascular disease burden: justified means for getting to the end.
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):580-6. doi: 10.1161/CIRCOUTCOMES.111.964072.
5
Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice.
Ann Rheum Dis. 2014 Jul;73(7):1284-8. doi: 10.1136/annrheumdis-2013-204792. Epub 2014 Mar 7.
6
Underutilisation of cardiovascular medications among at-risk individuals.
Int J Clin Pract. 2010 Apr;64(5):604-10. doi: 10.1111/j.1742-1241.2009.02258.x. Epub 2009 Nov 11.
7
Performance measures in million hearts: 2 partners' perspective.
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):587-8. doi: 10.1161/CIRCOUTCOMES.112.967018.
9
Personalized vascular medicine: individualizing drug therapy.
Vasc Med. 2011 Oct;16(5):391-404. doi: 10.1177/1358863X11422251.
10
Aspirin for primary prevention: yes or no?
J Prim Health Care. 2010 Jun;2(2):92-9.

引用本文的文献

1
Cardiovascular Imaging in the Era of Precision Medicine: Insights from Advanced Technologies - A Narrative Review.
Health Sci Rep. 2024 Oct 30;7(11):e70173. doi: 10.1002/hsr2.70173. eCollection 2024 Nov.
2
Mesenchymal stem cells as future treatment for cardiovascular regeneration and its challenges.
Ann Transl Med. 2024 Aug 1;12(4):73. doi: 10.21037/atm-23-1936. Epub 2023 Dec 29.
4
Early central cardiovagal dysfunction after high fat diet in a murine model.
Sci Rep. 2023 Apr 21;13(1):6550. doi: 10.1038/s41598-023-32492-w.
6
An Overview of Chemical and Biological Materials lead to Damage and Repair of Heart Tissue.
Cardiovasc Eng Technol. 2021 Oct;12(5):505-514. doi: 10.1007/s13239-021-00544-9. Epub 2021 May 27.
7
Current research trends and challenges in tissue engineering for mending broken hearts.
Life Sci. 2019 Jul 15;229:233-250. doi: 10.1016/j.lfs.2019.05.012. Epub 2019 May 17.
8
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.
Cochrane Database Syst Rev. 2017 Mar 6;3(3):CD009868. doi: 10.1002/14651858.CD009868.pub3.

本文引用的文献

2
Multiple risk factor interventions for primary prevention of coronary heart disease.
Cochrane Database Syst Rev. 2011 Jan 19;2011(1):CD001561. doi: 10.1002/14651858.CD001561.pub3.
3
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17.
4
By Jove! What is a clinician to make of JUPITER?
Arch Intern Med. 2010 Jun 28;170(12):1073-7. doi: 10.1001/archinternmed.2010.189.
7
Phospholipase A2s: developing drug targets for atherosclerosis.
Atherosclerosis. 2010 Oct;212(2):357-66. doi: 10.1016/j.atherosclerosis.2010.03.011. Epub 2010 Mar 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验